Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals’ Investigational Respiratory Syncytial Virus (RSV) Vaccines
Condition(s):Infections, Respiratory Syncytial VirusLast Updated:May 30, 2017Completed
Hide Studies Not Open or Pending
Condition(s):Infections, Respiratory Syncytial VirusLast Updated:May 30, 2017Completed
Condition(s):Acute Upper Respiratory Tract Infections; BronchitisLast Updated:October 5, 2010Completed
Condition(s):Respiratory Syncytial Virus ProphylaxisLast Updated:October 8, 2021Completed
Condition(s):Upper Respiratory Tract Infections; Pharyngitis; TonsillitisLast Updated:October 17, 2023Terminated
Condition(s):Respiratory Syncytial Virus InfectionsLast Updated:August 5, 2022Completed
Condition(s):Viral Respiratory InfectionLast Updated:May 17, 2022Completed
Condition(s):Respiratory Syncytial Virus InfectionsLast Updated:March 7, 2024Active, not recruiting
Condition(s):Respiratory Syncytial VirusLast Updated:February 9, 2024Active, not recruiting
Condition(s):Lower Respiratory Tract InfectionLast Updated:March 13, 2024Recruiting
Condition(s):Respiratory Syncytial Virus InfectionsLast Updated:September 16, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.